KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) EPS (Weighted Average and Diluted) (2016 - 2025)

Novartis Ag's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at $1167.8 for Q2 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 12.14% to $1167.8 in Q2 2025 year-over-year; TTM through Mar 2026 was $2746.1, a 53.77% decrease, with the full-year FY2025 number at $1955.8, down 3.86% from a year prior.
  • EPS (Weighted Average and Diluted) hit $1167.8 in Q2 2025 for Novartis Ag, down from $1187.4 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for NVS hit a ceiling of $2891.5 in Q2 2022 and a floor of $42.2 in Q2 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged $780.79 across 5 years, with a median of $560.3 in 2021.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 98.54% in 2023 and later surged 3049.31% in 2024.
  • Tracing NVS's EPS (Weighted Average and Diluted) over 5 years: stood at $560.3 in 2021, then tumbled by 90.2% to $54.91 in 2022, then decreased by 15.6% to $46.34 in 2023, then surged by 2462.27% to $1187.4 in 2024, then dropped by 1.65% to $1167.8 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for NVS at $1167.8 in Q2 2025, $1187.4 in Q4 2024, and $1329.1 in Q2 2024.